| 靶点: |
IC50: 3.9 nM (SOS1) |
| 体内研究: |
SOS1-IN-14 (50 mg/kg; p.o.; qd) exhibits 83.0% tumor suppression in Mia-paca-2 pancreas xenograft mice tumor models. SOS1-IN-14 shows a favorable pharmacokinetic profile with a bioavailability of 86.8% in beagles. Pharmacokinetic Parameters of SOS1-IN-14 (compound 13c) in ICR mice, Sprague-Dawley rats and Beagle dogs. |
| 参考文献: |
1. He H, et al. Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma. J Med Chem. 2022 Sep 29. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.816 ml |
9.081 ml |
18.163 ml |
| 5 mM |
0.363 ml |
1.816 ml |
3.633 ml |
| 10 mM |
0.182 ml |
0.908 ml |
1.816 ml |
| 50 mM |
0.036 ml |
0.182 ml |
0.363 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |